Cardium Therapeutics (OTCMKTS:CRXM) is a development-stage biopharmaceutical company focused on regenerative medicine and advanced drug delivery systems. The company’s core activities center on the research, development and commercialization of proprietary biologic and synthetic platforms designed to promote tissue repair and functional recovery across a range of clinical indications. Cardium pursues both internally developed programs and collaborative partnerships to advance its pipeline of therapeutic and medical device candidates.
Its product portfolio comprises specialized hydrogel matrices, cell-based therapies and antimicrobial barrier technologies intended for use in wound care, orthopedic and dental repair, and cardiovascular applications. Lead programs include a cell therapy targeting myocardial ischemia, as well as injectable scaffolds engineered to support bone regeneration and chronic wound management. Cardium’s drug delivery platforms leverage controlled-release features to optimize local bioactivity and minimize systemic exposure, setting the stage for novel treatment paradigms in regenerative medicine.
Founded in 1987 and headquartered in Houston, Texas, Cardium has built a global presence through strategic licensing and distribution agreements in Europe and Asia. The company’s clinical and manufacturing operations are supported by a network of contract research and contract manufacturing organizations, enabling scalable production and regulatory advancement of its drug and device candidates. Over the years, Cardium has navigated multiple corporate transformations to refine its strategic focus on high-value therapeutic areas with significant unmet medical needs.
Cardium’s leadership team brings together seasoned executives with extensive experience in biotechnology, medical devices and regulatory affairs. The organization is led by President and Chief Executive Officer William F. Caldwell, whose background spans clinical development and commercialization of biologic products. Supporting him is a cadre of senior leaders overseeing R&D, quality assurance, and global business development, all committed to driving Cardium’s mission of delivering innovative regenerative solutions to patients worldwide.
AI Generated. May Contain Errors.
Free CRXM Stock Alerts